Alpha healthcare Acquisition III announced a definitive business combination agreement with Carmell Therapeutics, a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications.
Terms call for Carmell's shareholders to receive 15 million shares of the SPAC's Class A stock. Assuming no redemptions, the market capitalization of the combined company would be approximately $328 million and it is estimated that the current shareholders of Carmell will own approximately 46% of the outstanding shares.
The combined company is expected to receive gross proceeds of $154 million at closing. The transaction is expected to close in the first half of the year.
Alpha Healthcare III raised $150 million in a July 2021 IPO. The SPAC is led by rajiv shukla
Carmell has raised more than $20 million from firms including Harbor Light Capital Partners, Medivate Partners and Keiretsu Forum. Read more.